CompanyHealthDeveloper Tools
Seneca Therapeutics, Inc.
Seneca Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic immunotherapeutics built on SVV-001, a non-pathogenic Seneca Valley Virus that selectively replicates in solid-tumor cells expressing the TEM8/ANTXR1 receptor. Founded by oncolytic-virus pioneer Dr. Paul Hallenbeck, the company pairs SVV-001 with immune modulators and checkpoint inhibitors to spark systemic anti-tumor immunity, and is advancing a Phase I/II trial in high-grade neuroendocrine neoplasms while building a pipeline of armed and neo-antigen viral constructs.
2015Founded
PhiladelphiaHQ
part of $24.8M total raisedEarlier rounds
oncolytic virusseneca valley virussvv-001cancer immunotherapysolid tumorstem8